As suggested by the in vivo studies of thiazolidinedionesin min mice, use of PPARγ agonists in colon cancer prevention mayrequire identification of high-risk individuals based on genetic susceptibilityas well as aberrant gene expression and signal transduction. The gene discussed is PPARG; the disease is malignant colon neoplasm.